This is an entirely free service. No payments are to be made. Also send me The Ultimate Guide to Profiting From Derivatives and sign me up for Profit Hunter,a free newsletter that focuses on identifying short term money making opportunities.Download NowSubscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.

Metal, banks bouy the markets

Tue, 5 Jan 11:30 am

The markets continued their northward journey on account of sustained buying activity witnessed during the previous two hours of trade. Though stocks across all sectors are witnessing a field day those from the metal and banking sectors are leading the pack of gainers.

The BSE-Sensex and NSE-Nifty indices are trading higher, up by 145 points and 45 points respectively. The BSE-Midcap and BSE-Smallcap indices are also trading higher, up by 1.3% and 1.1% respectively. The rupee is trading at 46.17 to the dollar.

According to a leading business daily, Tata group's jewellery and watch arm, Titan is looking to triple its revenue in the next 5 years. It plans to raise its topline from Rs 46 bn in this fiscal to Rs 140 bn by 2014-15. In the jewellery category which leads its topline, it plans to strengthen its position in the high-end designer jewellery segment. Tanishq is expected to contribute around Rs 100 bn by next 5 years. Here, it is diverting its focus from the recession-hit US market. It is planning to adopt a design-robust, diamond led and large store intensive strategy. The company sees a lot of opportunity in the Indian jewellery market which is slated to grow from Rs 800 bn to around 1,250bn by 2015. Rather than focusing on low-end everyday wear jewellery, the company will focus on wedding jewellery segment.

In the watch segment, it is diverting its focus towards smaller international markets like Vietnam, Oman and Qatar. We believe that the company's sales growth will be impacted in the current fiscal on account of rise in gold prices which dented the volumes.Nevertheless, its investment in brands should start paying off in the near future.

As per a leading business daily, Cipla, India's second largest pharma company (by market value) is in talks with leading global generic drug manufacturers like GSK and Israel's Teva for supplying generic drugs. Cipla is planning to strike a deal for one or two specific products and is not planning to sell any stake to any partner company. Cipla has been in a number of such negotiations with drug majors like GSK, Pfizer and Boehringer Ingelheim. It may be noted that global drug makers like GSK and Pfizer which are plagued by falling drug prices and increasing generic competition, are eyeing low-cost destinations like India as a source for supplies. This is good news for drug makers like Cipla as supply tie-ups will help their topline growth. Cipla is one of the world's largest producers of low-cost drugs for fighting HIV AIDS. Presently, it has a market value of US$ 5.5 bnand expects to rake in US$ 1.1 bn in sales for FY10.

OTHER USEFUL LINKS

MARKET STATS

ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.